Clinical trial NCT04904328: A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.
Official title: A Proof of Concept Clinical Investigation Designed to Evaluate the Performance of Lumishade® Lens With Frame in Alleviating the Symptoms of Photosensitive Migraine.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Migraine
Keywords: Migraine
Aura
Photosensitivity
Wavelength
Lens
Glasses
Lead sponsor: Mitsui Chemicals, Inc.
Sponsor class: INDUSTRY
First posted: 2021-05-27
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity.

The spectacles cut out blue light wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.

Detailed description: Patients will be randomised to one of two groups:

Group 1

1. Patients wear sham glasses for 4 weeks
2. Patients have 1 week's washout
3. Patients wear active glasses for 4 weeks

   Group 2
4. Patients wear active glasses for 4 weeks
5. Patients have 1 week's washout
6. Patients wear sham glasses for 4 weeks

The study will aim to determine whether wearing the active lens successfully reduces the symptoms of migraine, compared to wearing sham lens.

Assuming a fairly conservative SD in the primary endpoint of 8 points, a total of 56 participants would be required to have 90% power to detect a minimum clinically significant difference of 5 points in a two-sample t-test. Allowing for a 20% drop-out rate, 70 participants would need to be recruited.

Patients will be in the trial for a total of 13 weeks (4 week run-in, two 4 week periods, with 1 week washout in between).

Eligibility criteria: Inclusion Criteria:

1. Over 18 years old
2. Diagnosis of migraine before the age of 50, confirmed though screening consultation with the patient
3. Willing and able to provide written informed consent
4. Willing to comply with study assessment schedule and patient diary entry
5. Diagnosis of migraine, with or without aura based on the following primary headache characteristics (based on the Revised International Headache Society criteria for migraine headache)

   1. At least 5 attacks fulfilling criteria B-D
   2. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
   3. Headache has at least two of the following characteristics:

   i. unilateral location ii. pulsating quality iii. moderate or severe pain intensity iv. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) d. During headache at least one of the following: i. nausea and/or vomiting ii. photophobia and phonophobia e. Not attributed to another disorder
6. Migraine associated with photophobia i.e. either photic hypersensitivity or photic allodynia or inter-ictal photophobia or migraine triggered by light according to patient or a combination of these 4 factors
7. No expected changes of headache preventative medications after enrolment

Exclusion Criteria:

1. Patients with other light sensitive conditions, such as iritis or retinal disease.
2. Patients who have less than 4 headache days per month
3. Patients who have daily headaches.
4. Pregnant or nursing
5. History of cluster headache or hemiplegic migraine
6. Evidence of seizure or major psychiatric disorder
7. Score of 19 or higher on the BDI
8. Active chronic pain syndrome
9. Cardiac or hepatic disease
10. Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug
11. Have received Botox injections for any purpose in the head or face region within 3 months of trial onset or scheduled to receive such treatment during the trial
12. Medication overuse as per the revised ICHD-3 IHS criteria
13. Medications that can affect light perception like ethambutol, hydroxychloroquine or amiodarone or any other according to the opinion of the investigator
14. Patients requiring prescription/reading glasses
15. Patients who have not responded to three or more migraine preventive drugs
16. Patients who have a diagnosed neurological disorder that may influence the study according to the investigators

Primary outcomes:
measure: Headache Impact Test 6
timeFrame: up to 13 weeks for each patients participation
Secondary outcomes:
measure: Patient diary
timeFrame: up to 13 weeks for each patients participation
Other outcomes:
Locations:
Study officials:
References: